Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Trimethobenzamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.92 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.92 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | ACHE | P22303 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.90 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethobenzamide SCHEMBL6683399 | 0.96 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL28858 | 0.96 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586062 | 0.95 | DRD2 (0.98) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL41339 | 0.95 | SMN1; SMN2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586216 | 0.95 | SMN1; SMN2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586290 | 0.95 | DRD2 (0.98) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL3059009 | 0.94 | DRD2 (0.96) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586023 | 0.93 | DRD2 (0.94) | DRD2DRD3LMNAACHESLC6A2 | |
| Itopride SCHEMBL311309 | 0.85 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Itopride SCHEMBL554675 | 0.84 | DRD2 (0.98) | DRD2DRD3LMNAACHESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471888-A4 | ORAL TRIMETHOBENZAMIDE FORMULATIONS AND METHODS | KING PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1471888-A2 | ORAL TRIMETHOBENZAMIDE FORMULATIONS AND METHODS | King Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1471889-A2 | ORAL PEDIATRIC TRIMETHOBENZAMIDE FORMULATIONS AND METHODS | King Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040034102-A1 | Oral pediatric trimethobenzamide formulations and methods | KING PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040005354-A1 | Oral trimethobenzamide formulations and methods | KING PHARMACEUTICALS, INC. (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003072021-A2 | ORAL PEDIATRIC TRIMETHOBENZAMIDE FORMULATIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072022-A2 | ORAL TRIMETHOBENZAMIDE FORMULATIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005354-A1 | Oral trimethobenzamide formulations and methods | TMT1A, TH, VIP | DRD2 2497/4885DRD3 2721/4885SLC6A2 310/4885 |
| US-20040034102-A1 | Oral pediatric trimethobenzamide formulations and methods | TH, TMT1A, HNMT | DRD2 2210/4885DRD3 2377/4885SLC6A2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.